The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Findings for Cemiplimab in Advanced or Recurrent Cervical Cancer

Danny Rischin, MD, MBBS, FRACP
Published Online:8:07 PM, Thu January 3, 2019


Danny Rischin, MD, MBBS, FRACP, director of the Division of Cancer Medicine and head of the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.

Cemiplimab, a PD-1 monoclonal antibody, was given as a single agent, as well as in combination with radiotherapy in a second cohort. Each of the 2 cohorts had a partial response, Rischin notes.

Also, some patients had durable disease control, which Rischin explains as at least 3 months without disease progression.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.